You A, Gu J, Wang J, Li J, Zhang Y, Rao G, Ge X, Zhang K, Gao X, Wang D
The Fourth Department of Neurosurgery, Tangshan Gongren Hospital, 063000 Tangshan, China.
Operating Theatre, Tangshan Central Hospital, 063000 Tangshan, China.
Neurologia (Engl Ed). 2024 May;39(4):353-360. doi: 10.1016/j.nrleng.2021.06.008.
Glioma presents high incidence and poor prognosis, and therefore more effective treatments are needed. Studies have confirmed that long non-coding RNAs (lncRNAs) basically regulate various human diseases including glioma. It has been theorized that HAS2-AS1 serves as an lncRNA to exert an oncogenic role in varying cancers. This study aimed to assess the value of lncRNA HAS2-AS1 as a diagnostic and prognostic marker for glioma.
The miRNA expression data and clinical data of glioma were downloaded from the TCGA database for differential analysis and survival analysis. In addition, pathological specimens and specimens of adjacent normal tissue from 80 patients with glioma were used to observe the expression of HAS2-AS1. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic ability and prognostic value of HAS2-AS1 in glioma. Meanwhile, a Kaplan-Meier survival curve was plotted to evaluate the survival of glioma patients with different HAS2-AS1 expression levels.
HAS2-AS1 was significantly upregulated in glioma tissues compared with normal tissue. The survival curves showed that overexpression of HAS2-AS1 was associated with poor overall survival (OS) and progression-free survival (PFS). Several clinicopathological factors of glioma patients, including tumor size and WHO grade, were significantly correlated with HAS2-AS1 expression in tissues. The ROC curve showed an area under the curve (AUC) value of 0.863, indicating that HAS2-AS1 had good diagnostic value. The ROC curve for the predicted OS showed an AUC of 0.906, while the ROC curve for predicted PFS showed an AUC of 0.88. Both suggested that overexpression of HAS2-AS1 was associated with poor prognosis.
Normal tissues could be clearly distinguished from glioma tissues based on HAS2-AS1 expression. Moreover, overexpression of HAS2-AS1 indicated poor prognosis in glioma patients. Therefore, HAS2-AS1 could be used as a diagnostic and prognostic marker for glioma.
胶质瘤发病率高且预后差，因此需要更有效的治疗方法。研究证实，长链非编码RNA（lncRNA）基本可调控包括胶质瘤在内的各种人类疾病。理论上认为，HAS2-AS1作为一种lncRNA在多种癌症中发挥致癌作用。本研究旨在评估lncRNA HAS2-AS1作为胶质瘤诊断和预后标志物的价值。
从TCGA数据库下载胶质瘤的miRNA表达数据和临床数据进行差异分析和生存分析。此外，使用80例胶质瘤患者的病理标本和相邻正常组织标本观察HAS2-AS1的表达。采用受试者工作特征（ROC）曲线分析HAS2-AS1在胶质瘤中的诊断能力和预后价值。同时，绘制Kaplan-Meier生存曲线以评估不同HAS2-AS1表达水平的胶质瘤患者的生存情况。
与正常组织相比，HAS2-AS1在胶质瘤组织中显著上调。生存曲线显示，HAS2-AS1的过表达与总体生存期（OS）和无进展生存期（PFS）较差相关。胶质瘤患者的几个临床病理因素，包括肿瘤大小和WHO分级，与组织中HAS2-AS1的表达显著相关。ROC曲线显示曲线下面积（AUC）值为0.863，表明HAS2-AS1具有良好的诊断价值。预测OS的ROC曲线AUC为0.906，而预测PFS的ROC曲线AUC为0.88。两者均表明HAS2-AS1的过表达与预后不良相关。
基于HAS2-AS1的表达可以清楚地区分正常组织和胶质瘤组织。此外，HAS2-AS1的过表达表明胶质瘤患者预后不良。因此，HAS2-AS1可作为胶质瘤的诊断和预后标志物。
